Every clinical trial depends on a complex infrastructure of regulatory documents: protocols, informed consent forms, investigator brochures, and clinical study reports. For decades, producing these documents has been almost entirely manual work by experienced medical and regulatory writers. Now, AI tools using large language models and natural language processing are beginning to assist with drafting, consistency checking, and quality review.
The challenges are real. Recent data from Tufts CSDD shows that protocols with at least one substantial amendment increased from 57% to 76% since 2015, with the average number of amendments per protocol rising 60%. The time from identifying an amendment need to final ethics approval now averages 260 days, nearly triple the timeframe from a decade ago.
Current AI applications fall into three categories: automated first-draft generation for protocols and ICFs, cross-document consistency checking to catch discrepancies across the document suite, and data-to-text generation for clinical study reports. Research shows promise, with specialized systems achieving near-100% compliance with FDA regulatory rules for ICF structure in controlled conditions. However, hallucination rates, even when low, carry real consequences in regulatory submissions. Every serious implementation currently requires human-in-the-loop review to verify accuracy and maintain document integrity.